Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Department of Internal Medicine, Hiroshima City Funairi Citizens Hospital, Hiroshima, Japan.
Front Immunol. 2023 Jul 26;14:1217206. doi: 10.3389/fimmu.2023.1217206. eCollection 2023.
Vaccination against severe acute respiratory syndrome coronavirus type 2 is highly effective in preventing infection and reducing the severity of coronavirus disease (COVID-19). However, acquired humoral immunity wanes within six months. Focusing on the different tempo of acquisition and attenuation of specific antibody titers in individuals, we investigated the impact of genetic polymorphisms on antibody production after COVID-19 vaccination.
In total 236 healthcare workers from a Japanese municipal hospital, who received two doses of the vaccine were recruited. We employed a candidate gene approach to identify the target genetic polymorphisms affecting antibody production after vaccination. DNA samples from the study populations were genotyped for 33 polymorphisms in 15 distinct candidate genes encoding proteins involved in antigen-presenting cell activation, T cell activation, T-B interaction, and B cell survival. We measured total anti-SARS-Cov2 spike IgG antibody titers and analyzed the association with genetic polymorphisms at several time points after vaccination using an unbiased statistical method, and stepwise logistic regression following multivariate regression.
Significant associations were observed between seven SNPs in , and , and antibody titers at 3 weeks after the first vaccination as an initial response. Six SNPs in , and were associated with high responders with serum antibody titer > 4000 BAU/ml as boosting effect at 3 weeks after the second vaccination. Analysis of long-term maintenance showed the significance of the three SNPs in , and for the maintenance of antibody titers and that in for attenuation of neutralizing antibodies. Finally, we proposed a predictive model composed of gene profiles to identify the individuals with rapid antibody attenuation by receiver operating characteristic (ROC) analysis (area under the curve (AUC)= 0.76, sensitivity = 82.5%, specificity=67.8%).
The candidate gene approach successfully showed shifting responsible gene profiles and initial and boosting effect mainly related to the priming phase into antibody maintenance including B cell survival, which traces the phase of immune reactions. These gene profiles provide valuable information for further investigation of humoral immunity against COVID-19 and for building a strategy for personalized vaccine schedules.
接种严重急性呼吸综合征冠状病毒 2 型疫苗可有效预防感染和降低冠状病毒病(COVID-19)的严重程度。然而,获得的体液免疫会在六个月内减弱。鉴于个体中特异性抗体滴度的获得和衰减速度不同,我们研究了遗传多态性对 COVID-19 疫苗接种后抗体产生的影响。
共招募了来自日本一家市立医院的 236 名医护人员,他们接受了两剂疫苗接种。我们采用候选基因方法,确定了影响疫苗接种后抗体产生的目标遗传多态性。从研究人群中提取 DNA 样本,对编码参与抗原呈递细胞激活、T 细胞激活、T-B 相互作用和 B 细胞存活的 15 个不同候选基因的 33 个多态性进行基因分型。我们测量了总抗 SARS-CoV2 刺突 IgG 抗体滴度,并使用无偏统计方法和多元回归后的逐步逻辑回归,在接种后几个时间点分析了与遗传多态性的关联。
在首次接种后 3 周的初始反应中,观察到与 、和中的 7 个 SNP 之间存在显著关联。在第二次接种后 3 周的增强效应中,与高应答者(血清抗体滴度>4000 BAU/ml)相关的是 6 个 SNP 中的、和。长期维持分析显示,、和中的 3 个 SNP 与抗体滴度的维持有关,而 中的 SNP 与中和抗体的衰减有关。最后,我们通过接收者操作特征(ROC)分析(曲线下面积(AUC)=0.76,敏感性=82.5%,特异性=67.8%)提出了一个由基因谱组成的预测模型,用于识别抗体衰减较快的个体。
候选基因方法成功地显示了负责基因谱的转变,以及与初始和增强效应主要相关的免疫反应阶段的抗体维持,包括 B 细胞存活。这些基因谱为进一步研究 COVID-19 的体液免疫以及建立个性化疫苗接种方案提供了有价值的信息。